Quick Facts About WuXi AppTec: Accelerating the development of new life-saving treatments for patients around the world 

Last Updated: February 2026

Prepared by WuXi AppTec Content Team 

A trusted partner to customers in the global healthcare community, we help develop life-saving treatments and advance pharmaceutical and life sciences innovations – while adhering to the highest standards of compliance, security, and ethics.

Who We Are

WuXi AppTec is a global contract research, development, and manufacturing organization (CRDMO) serving the pharmaceutical and life sciences industries. Founded in 2000, we work with companies of all sizes — from emerging biotech startups to leading multinational pharmaceutical firms — to help bring innovative medicines and therapies to patients in need. 

Our mission is to help our customers discover, develop and manufacture pharmaceuticals and healthcare products to benefit patients globally.

By The Numbers 

• Operations in 30+ countries serving the global life sciences ecosystem
• 33,000+ employees across Asia, Europe, and North America
• In 2025, customers and regulatory authorities performed over 700 quality audits and inspections with zero critical finding

Our Ownership and Governance

• WuXi AppTec is a publicly traded commercial enterprise with a diverse global shareholder base. 

• Our institutional investors represent leading capital from the United States, Europe, Asia, and the Middle East. We operate with a fiduciary responsibility to create value for all shareholders through transparent, market-driven operations.

• Our board of directors and senior executive management team are comprised of established scientists and businesspeople, none of whom has a military background or political party affiliation. 

Our Role in the Global Supply Chain

• WuXi AppTec is one of many contract service organizations supporting the global pharmaceutical and life sciences industries through our unique CRDMO model.

• We are a trusted partner to customers across more than 30 countries, and the work we do at facilities across Asia, Europe and the U.S. enables their development and delivery of medicines and therapies to patients around the world.

• We do not have exclusive service agreements with our customers, enabling them to work with multiple suppliers to ensure resilience. 

Data Security, Privacy and Regulatory Oversight

• We operate under strict U.S. data privacy and intellectual property guidelines, including those set by the U.S. Department of Health & Human Services, Federal Trade Commission, and Food & Drug Administration.

• All project data is compartmentalized by customer and accessible only to authorized personnel. 

• U.S.-based project information is stored exclusively in U.S.-based facilities and IT systems, separated by robust firewalls from operations in other countries. 

• In 2025, the company completed 60 customer information security audits, with a 100% pass rate and no critical findings. 

More Information

To learn more about our governance, compliance, and operations, please visit: 

• [Annual Reports and Corporate Governance Policies] 

  • Corporate Governance

• [Financial Reports and Presentations] 

  • Financial Reports and Presentations

• [Business Conduct & Ethics, Data Security and Privacy Statement] 

  • Business Conduct and Ethics

• [Supply Chain and Compliance Overview]

  • CRDMO Supply Chain